The addition of tislelizumab to chemotherapy significantly extended OS for patients with previously untreated advanced esophageal squamous cell carcinoma, according to a press release from the agent’s manufacturer.The combination conferred the survival benefit among patients with unresectable, locally advanced, recurrent or metastatic disease regardless of PD-L1 expression, an interim analysis of the randomized phase 3 RATIONALE 306 study showed. It also had a safety profile consistent with that observed in previous trials.“We are encouraged by the survival benefit seen in theRead More